Milvexian, also known as BMS-986177 and JNJ-70033093, is a blood coagulation factor XIa inhibitor. Milvexian demonstrated good selectivity over plasma kallikreinKi = 44 nM (400-fold selective), and chymotrypsinKi = 35 nM (318-fold selective). At a dose of 1.5 mg kg, Milvexian exhibited an overall exposure of 1215 nM h, low clearance of 10.3 mL min kg, and oral bioavailability of 32%.